ANC Consulting
"Our chief want is someone who will inspire us to be what we know we could be."
Ralph Waldo Emerson
Strong science is rarely what closes a round. Strong positioning is.
ANC Consulting works with early-stage biotech and healthcare founders on the moments that decide whether a round closes, a partnership lands, or a deal holds. The work spans asset positioning, partner identification, fundraising preparation, and deal structuring.
Engagements are project-based, scoped to a clear outcome: senior, hands-on, confidential. Where the fit is strong on both sides, the relationship continues on a retainer basis: an ongoing seat at the strategic table, available across the questions that arise between deals.
The work that matters for partnership in biotech is the diligence that comes before it and the structure that survives it. There's the financial logic of the term sheet and the honest assessment of what the deal is actually worth. And there's what's underneath the conversation. The asset's real story. The deal terms that hold. The read on which counterpart actually has the budget. That's where ANC operates.
From scientific story to investor-ready ask.
Diligence on the asset (scientific rationale, competitive landscape, commercial viability) and an honest read on where it's strong, where it's exposed, and what it takes to close the gap. From there: the narrative, the deck, the data room. Mapping investor targets to the round size and the stage. Coaching the founder through the meeting cycle.
From the right counterpart to the deal that holds.
Positioning the asset for the partnership market. Identifying the right pharma counterparts, in the right therapeutic areas, at the right stage of their pipeline. Then term sheet review, deal architecture, and negotiation support. Agreements that work for both sides and survive contact with the legal teams.
Founders speak science.
Investors speak capital.
Partners speak terms.
Few people speak all three fluently enough to engineer the decisions where money, asset, and counterpart converge. That's the work.
Eighteen years in business development across pharma, biotech, medical devices, and in-vitro diagnostics. The work has spanned therapeutic areas (oncology, CNS, cardiovascular) and regions (Europe, MENA, North America), but the underlying skill has been the same: reading an asset, reading a counterpart, and finding the structure that gets a deal done.
The path started in science (pharmacy degree, then genetics research) and moved into commercial work through medical devices and diagnostics before settling into biotech. That trajectory is the point: combining technical literacy with deal experience is what makes the diligence honest and the conversations land.
Pharm. D., M.Sc., MBA. Formal training at Denis Diderot University, Pierre et Marie Curie University, Sorbonne University. Executive training at Imperial College London, and Columbia Business School.
Working in English, French, Spanish, Italian, and Arabic.